(Q40609049)

22 September 2017

title

Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis (English)

1 reference

22 September 2017

0 references

Sunanda Kane

1

1 reference

22 September 2017

Dezheng Huo

series ordinal

2

1 reference

22 September 2017

James Aikens

series ordinal

3

1 reference

22 September 2017

Stephen Hanauer

series ordinal

4

1 reference

22 September 2017

language of work or name

English

0 references

publication date

1 January 2003

1 reference

American Journal of Medicine

22 September 2017

published in

1 reference

22 September 2017

volume

114

1 reference

22 September 2017

issue

1

1 reference

22 September 2017

page(s)

39-43

1 reference

Cigarette smoking and ulcerative colitis: a case-control study.

22 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901383-9

Effects of smoking on the presentation and clinical course of inflammatory bowel disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901383-9

Non-steroidal anti-inflammatory drugs are associated with emergency admission to hospital for colitis due to inflammatory bowel disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901383-9

Effects of nonsteroidal antiinflammatory drugs on inflammatory bowel disease: a case-control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901383-9

An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis. A randomized, placebo-controlled trial. The Mesalamine Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901383-9

Coated oral 5-aminosalicylic acid (Claversal) is equivalent to sulfasalazine for remission maintenance in ulcerative colitis. A double-blind study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901383-9

Comparison of the efficacy and safety of 1.5 compared with 3.0 g oral slow-release mesalazine (Pentasa) in the maintenance treatment of ulcerative colitis. Dutch Pentasa Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901383-9

Maintenance of remission of ulcerative colitis: a comparison between balsalazide 3 g daily and mesalazine 1.2 g daily over 12 months. ABACUS Investigator group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901383-9

Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Pentasa UC Maintenance Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901383-9

Telephoning the patient's pharmacy to assess adherence with asthma medications by measuring refill rate for prescriptions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901383-9

A comparison study of multiple measures of adherence to HIV protease inhibitors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901383-9

Observational studies of antihypertensive medication use and compliance: is drug choice a factor in treatment adherence?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901383-9

Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901383-9

A general method of compliance assessment using centralized pharmacy records. Description and validation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901383-9

Cortisone in ulcerative colitis; final report on a therapeutic trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901383-9

Why do patients with ulcerative colitis relapse?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901383-9

The assessment of refill compliance using pharmacy records: methods, validity, and applications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901383-9

Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901383-9

Course of ulcerative colitis: analysis of changes in disease activity over years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901383-9

A randomized controlled trial of an enhanced patient compliance program for Helicobacter pylori therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901383-9

Increasing patient adherence to gastroenterology treatment and prevention regimens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901383-9

10.1016/S0002-9343(02)01383-9

7 January 2021

Identifiers

DOI

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/o2zrrtdicfdlfmtlxf4gpifw2e

mapped directly with Wikidata item

30 July 2022

based on heuristic

Fatcat ID

release_o2zrrtdicfdlfmtlxf4gpifw2e

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/o2zrrtdicfdlfmtlxf4gpifw2e

mapped directly with Wikidata item

30 July 2022

based on heuristic

https://api.fatcat.wiki/v0/release/o2zrrtdicfdlfmtlxf4gpifw2e

1 reference